Inotiv, Inc.

1.3300-0.01 (-0.75%)

Oct 29, 4:00:01 PM EDT · NasdaqCM · NOTV · USD

Upcoming Earnings

Report date

Dec 2, 2025 (in 33 days)

Key Stats

Market Cap

45.69M

P/E (TTM)

Basic EPS (TTM)

-2.62

Dividend Yield

Recent Filings

8-K

Inotiv settles securities suits

9/25/25Sep 25, 2025

Inotiv settled its securities class action for $8.75 million in cash, fully covered by insurance, resolving claims tied to its 2021 Envigo acquisition without admitting liability. The derivative suits wrap up with governance tweaks like splitting CEO and chair roles for five years, plus $2.25 million max in plaintiff fees from insurance. Ongoing privacy suits stem from August's cyber breach, disrupting operations while full impacts remain unclear. Settlements clear litigation overhang.

8-K

Cybersecurity breach disrupts operations

8/18/25Aug 18, 2025

Inotiv disclosed a cybersecurity incident on August 8, 2025, where a threat actor encrypted certain systems, disrupting network access and business applications. The company contained the breach, engaged specialists, notified law enforcement, and shifted to offline operations to minimize downtime. Full impacts remain unknown. Restoration timeline unclear.

10-Q

Q3 FY2025 results

8/7/25Aug 7, 2025

Inotiv's Q3 FY2025 revenue climbed 23.5% y/y to $130.7M, fueled by a 34.1% surge in RMS from higher NHP volumes and pricing, while DSA grew 8.9% on toxicology services; yet operating loss narrowed to $5.7M from $20.8M, thanks to lower one-time charges. YTD revenue rose 4.0% to $374.9M, with net loss shrinking to $60.1M or $1.89 diluted EPS from $90.0M or $3.46, confirmed against 31.8M shares—no anti-dilution flagged. Cash dipped to $6.2M amid $24.8M operating outflows, offset by $27.5M equity raise; free cash flow not disclosed in the 10-Q. Debt stands at $396.5M net, with $15M revolver available and covenant compliance holding. Revenue turned the corner.

8-K

Q3 revenue up 23.5%

8/6/25Aug 6, 2025

Inotiv reported Q3 fiscal 2025 revenue surging 23.5% to $130.7 million, fueled by 34.1% growth in Research Models & Services from higher non-human primate demand, while Discovery & Safety Assessment rose 8.9%. Net loss narrowed to $17.6 million from $26.1 million last year, with Adjusted EBITDA flipping to $11.6 million. DSA awards climbed 25% year-over-year. Revenue momentum builds, yet cash dipped to $6.2 million amid ongoing litigation risks.

8-K

SEC closes Inotiv probe

6/4/25Jun 4, 2025

Inotiv received SEC notice on June 2, 2025, closing its investigation into the company's importation of non-human primates from Asia since 2017, including potential Foreign Corrupt Practices Act violations. The Division of Enforcement, after reviewing documents and a formal probe started in January 2024, decided against recommending any action. Relief washes over Inotiv. This clears a major overhang, freeing focus on core operations without disclosed penalties or further risks.

About

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. It operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

CEO

Mr. Robert W. Leasure Jr.

IPO

11/25/1997

Website

https://www.inotiv.com

Employees

1,977

Sector

Healthcare

Industry

Diagnostics & Research